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ABSTRACT
South African organic chemistry is deeply rooted in a rich history of natural product chemistry research with the secondary
metabolites emanating from South Africa’s unique floral kingdoms dominating this research for nearly a century. However,
South Africa’s terrestrial biodiversity is exceeded by an even greater diversity of marine flora and fauna occurring off its coast,
which remain a relatively untapped source of novel biomolecules with unrealized pharmaceutical and agrochemical potential.
Examples of the seemingly endless opportunities arising from exploration of the diverse bioactivities of South African plant and
marine natural products, together with their semi-synthetic analogues, are presented here.
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1. Introduction
The first Frank Warren Lecture entitled ‘Lingering amongst
the Labiatae’ was presented by the late Douglas Rivett at the
inaugural Frank Warren Conference also held at the University
of KwaZulu-Natal (formerly the University of Natal) in Pieter-
maritzburg in 1983.1 One of the great characters or South African
academia and a doyen of natural products chemistry in this
country, Douglas Rivett, amongst many other achievements,
was the first South African to publish research chemistry contin-
uously over seven decades (1946–2005). Adapted from the 11th
Frank Warren Lecture, this paper is dedicated to the memory of
Douglas Rivett who sadly passed away shortly after the 2010
Frank Warren Lecture was delivered.
Rivett’s inaugural Frank Warren lecture focused on the
chemistry of labdane diterpene natural products from endemic
South African plants of the ‘mint’ family (Lamiaceae – formerly
Labiatae).1 Since then natural products research in South
Africa, in line with global trends, has been subjected to fluctuat-
ing fortunes largely driven by increasingly limited financial
support for this field of research endeavour. With a history of
over a century of active natural products research coupled to a
vast and unique biodiversity, South Africa is well placed to
exploit the recently predicted upswing in international
natural products research.2 This paper briefly overviews the
history and present status of natural product research in South
Africa and, taking examples from our two decades of research in
the South African marine environment, will highlight the
endless opportunities provided by a study of the marine natural
products unique to this exceptionally biodiverse region of the
world.
2. Plant Natural Products Research in South Africa – End
of an Era?
Brown3 and, more recently, Mulholland and Drewes4 have
drawn attention to the rich history of natural products research
in South Africa and the pivotal role which studies of indigenous
plant natural products have played in the development of South
African organic chemistry. Emerging from the chemical litera-
ture, and the historical perspectives provided by Brown,
Mullholland and Drewes, it is clear that there has not been a
single era of natural product chemistry research in South Africa
but rather three sequentially overlapping eras which will be
referred to here as the poisonous plant era, the specialization era
and the IKS era.
2.1. The Poisonous Plant Era (ca. 1902–1960)
The poisonous plant era was driven by the socio-economic
imperatives of agriculture in early 20th century South Africa.
Understandably, widespread livestock losses caused by the
ingestion of the many, then largely unknown, poisonous plants
that litter the South African veld were not sustainable in the
developing, largely pastoral, South African agro-economy. For
example an estimated one million sheep died from vomiting
disease (‘vermeersiekte’) in the Karoo region of South Africa
during the 1920s as a result of eating the plant Geigeria aspera the
source of the emetic toxin, geigerin (1).4 Instances of toxic plant
poisoning were not limited to livestock and a case of bread
poisoning in the Mossel Bay and George areas in 1933 was linked
to contamination of bread flour with alkaloids from indigenous
Senecio species.3
From as early as 1918 the role which Senecio plants also played
in the onset of cirrhosis of the liver (‘dunsiekte’) in South African
cattle and horses was well known.3,4 While much of the early
work on the chemistry of poisonous plants, e.g. Senecio species
was carried out at Onderstepoort near Pretoria, research into
plant toxins did not remain confined to this Government veteri-
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nary research facility as the 20th century unfolded. At the Uni-
versity of Natal, Frank Louis Warren, widely revered patriarch
of South African organic chemistry, entered the endemic plant
toxin field in 1943, with the publication of the chemical structure
(sans relative or absolute configuration) of the pyrrolizidine
alkaloid rosmarinine (2) isolated from S. rosmarinifolius.5 The
elucidation of the chemical structure of 2 ushered in for Warren a
life’s work in the pyrrolizidine alkaloid field that would bring
him both national and international recognition.3 Of all the
toxins isolated from South African poisonous plants during this
era, monofluroacetic acid (3) stands alone in its structural
simplicity, potent toxicity and significance as a plant toxin lethal
to all animals. Identified as the toxic principal in the endemic
plant Dichapetalum cymosum (‘gifblaar’) 3 was the first fluorinated
metabolite to be isolated from a plant and although it has now
shown to be ubiquitous in many toxic tropical plants, interest in
3 and its source plant, D. cymosum, remains unabated after nearly
a century of investigation.3,4
2.2. The Specialization Era (ca. 1960–1990)
Fifteen years after the Second World War, in a time of relative
prosperity coupled with increasing political turmoil in South
Africa, an era dawned in South African natural product chemistry
possibly best retrospectively described as the ‘natural product
specialization era.’ Specialization took two forms. Firstly,
specialization in terms of natural product investigations linked
to a specific plant family, e.g. amongst others, Rivett1,6 at Rhodes
University (Lamiaceae) and Taylor7 at the University of Natal in
Durban (Meliaceae) and secondly, specialization within indus-
trially and agriculturally important classes of natural products,
e.g. flavonoids and proanthocyanidins (condensed tannins) at
the University of the Orange Free State (Roux, Ferreira, Brandt,
Bezuidenhout et al.)8 and mycotoxins at the CSIR in Pretoria
(Steyn, Vleggaar, van Heerden, Horak, Gorst-Allman et al.).9 A
plethora of new chemical entities emerged from this relatively
well-resourced ‘golden era’ in South African natural product
chemistry and a selection of the structurally diverse secondary
metabolites isolated and identified by the individuals and
groups vide supra include the β–furano-di and triterpenoids,
dubiin (4)6 and ekebergin (5)7 from the Lamiaceae and Meliaceae,
respectively, the proanthocyanidin robetinidol-(4α, 8)-catechin
(6)8 and the mycotoxin janthitrem (7).9
2.3. The IKS Era (ca. 1990–2020)
The advent of political and social change in South Africa in
1994 saw a shift in the focus of natural products research towards
the study of traditional plant-based medicines as part of a wider
indigenous knowledge systems (IKS) national research priority
area. The natural products chemistry of traditional herbal reme-
dies, however, was not a new area of research endeavour in
South  Africa  and  natural  product  studies  of  plants  such  as
‘devil’s claw’ (Harpagophytum sp.) and the Hoodia cactus, sources
of the anti-arthritic harpagoside (8)10 and the triterpene
glycoside appetite suppressant (9),11 respectively, were initiated
in the 1970s and were far advanced when this era dawned. The
increasing worldwide interest, especially in Western Europe, in
plant extracts as a form of alternative or complementary medi-
cine, promises a bright future for South Africa’s many traditional
herbal medicines and this era, in all likelihood, is set to continue
unabated over the next decade.
2.4. South African Natural Products in the International Drug
Discovery Pipeline
Natural products still remain the mainstay of global new drug
discovery, especially in the battle against cancer. A recent review
of the contribution of natural products to anti-cancer drug
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discovery reveals that 63 % of the anti-cancer drugs entering the
market in the last 30 years have either a direct or indirect connec-
tion to natural products.12 Paradoxically, despite southern
Africa’s position as the third most biodiverse region of the
world,13 only two South African natural products, fosbretabulin
(combretastatin A4 phosphate, 10) and platensimycin (11) are
currently in the drug discovery pipeline. Combretastatin (12)
was first isolated from the South African Cape bush willow
(Combretum caffrum) by Pettit et al.14 Currently under development
as the anti-cancer drug (Zybrestat®) by the pharmaceutical
company Oxigene, the phosphorylated analogue (10) of
combretastatin is currently registered in a number of clinical
trials including Phase III trials against thyroid cancer in combi-
nation chemotherapy with taxol and carboplatin.15 Platensi-
mycin (11) was discovered by Merck in 2006 from a soil isolate
(Streptomyces platensis) collected in South Africa. Emerging from
the systematic screening of approximately 250 000 natural product
extracts (over 83 000 microbial strains cultured under three
different growth conditions) 11 is one of the few compounds
active against methicillin-resistant Staphylococcus aureus (MRSA)
with no observed general toxicity and thus great promise as a
future antibiotic.16 The controversial Hoodia appetite suppres-
sant 9, licensed by the CSIR initially to Phytopharm and then to
Pfizer, initially promised much but has yet to deliver on this
promise.10
3. Marine Natural Products Research in South Africa –
An Endless Opportunity?
The oceans, which cover 70 % of the earth’s surface and
comprise 95 % of its biosphere, remain the greatest unexploited
cornucopia of biomolecular diversity on the planet and an osten-
sibly infinite source of new chemical entities with exploitable
medicinal or agrochemical properties.17 Many marine organisms
(invertebrates, algae and microorganisms) produce natural
products as a chemical defence against predation or in a chemi-
cally mediated response to, amongst others, interspecific
competition for limited resources (e.g. space on a reef or access to
nutrients) and intraspecific communication (e.g. larval settling
cues). The coastline of southern Africa, stretching approximately
3000 km from southern Namibia in the west to southern Mozam-
bique in the east, sustains a unique and relatively accessible
diversity of endemic marine fauna and flora that can offer rich
rewards for marine natural products chemists in search of novel
bioactive secondary metabolites with possible medicinal proper-
ties. Over the last two decades the marine natural products
research group at Rhodes University has isolated a plethora of
new bioactive natural products from southern African marine
organisms18 and selected examples of the seemingly endless
opportunities arising from our marine natural products research
over this period are presented here.
3.1. Limpets, Labdanes and Crop Diseases
The secretive mollusc, Trimusculus costatus, occurs in dense
colonies hanging upside down under rock ledges in the
intertidal zone near Cintsa on the southeast coast of South
Africa.19 By remaining hidden and possessing a shell, T. costatus is
protected from terrestrial predators and desiccation during low
tide. However, this mollusc also has to contend with the atten-
tions of predatory fish, and carnivorous sea stars, when sub-
merged at high tide for which the presence of a shell offers only
limited protection. Interestingly, when subjected to predation,
Trimusculus species, in common with some other shelled
molluscs, are able to extend their inverted muscular ‘foot’ over
the top of their shell to expose rows of small glands on the under-
side of the foot which produce a feeding-deterrent-containing
white mucus to repel predators.20
In a series of feeding assays using the common intertidal
omnivorous predatory fish Pomadasys commersonnii we estab-
lished that the two major feeding deterrents produced by
T. costatus were the labdane diterpenes (13 and 14).19,21 Of interest
to us, given the well-documented history of labdane diterpene
research at Rhodes University,1 was the structural similarity
between these two compounds and the labdane diterpenes
hispanone (15) and rhinocerotinoic acid (16) isolated from two
endemic South African plants of the Family Lamiaceae: Ballota
africana and Elytropappus rhinocerotis, respectively.22,23 Our
attention was drawn to the sterically unfavourable, diaxial
arrangement of the acetoxy functionalities at C-6 and C-7 in the
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two Trimusculus metabolites, 13 and 14, and we hypothesized
that the introduction of a similar diaxial configuration of either
acetoxy or hydroxy groups in 15 and 16 may enhance the
bioactivity of these latter plant secondary metabolites.
From the outset we recognized the usefulness of the α,β-unsat-
urated ketone moiety in directing further oxygenation at C-6 in
15 and 16. Both C-6 hydroxy epimers (17 and 18) of the more
readily available 15 were accordingly synthesized via Vedejs’
oxidative procedure.24 Standard hydride reduction of 17 yielded
an epimeric mixture of 19 and 20 with the former more sterically
hindered target compound, not unexpectedly, emerging in low
yield (25 %).25 Interestingly, sodium borohydride reduction of
6β-acetoxyhispanone (21), prepared via manganic acetate oxida-
tion of 15, afforded only 6β-acetoxy-7β-hydroxyhispanone (22).25
Eager to increase the quantity of 19 available for bioactivity
studies we proceeded to saponify 21 with ethanolic potassium
hydroxide in an attempt to initially provide 17 which could then
be reduced to 19 and 20. To our surprise the major product of this
saponification was the diosphenol (23) and not 17, as antici-
pated.25 Undeterred, we re-attempted the saponification of 21
using Mori’s milder potassium cyanide saponification procedure
to obtain, again unexpectedly, only the nitriles (24 and 25) as the
major and minor products (45 and 9 %, respectively).26 We
subsequently proposed that 24 was formed through an initial
stereospecific Michael addition of a cyanide nucleophile at C-9
in 21 followed by a 1,2-carbonyl transposition via a classical
Lobry de Bruyn-van Ekenstein rearrangement of an α-hydroxy
ketone. Compounds 24 and 25 represented the first example of
labdane diterpenes with a cyano substituent at C-9.
Opportunities to screen South African marine and plant
natural products in a wide diversity of national and interna-
tional biomedical and agrochemical screening programmes
have been regularly presented to us over the last two decades.
At the time we were involved in the Trimusculus research we
were part of a collaborative agrochemical screening programme
with Dow AgroSciences in the USA. Of the approximately
50 diterpene natural products and semi-synthetic derivatives
(including 15–25) submitted from our laboratory into this
screening programme over a period of two years, only 24 and 25
exhibited significant activity in agrochemical screens against
wheat rust (Puccinia recondite) and rice blast (Magnaporthe grisea)
fungi.26 The latter crop disease is responsible for the destruction
of an estimated 50 % of the annual global rice crop and given
the need for new chemical entities active against rice blast the
activity of 24 observed in in vitro assays was deemed significant
enough to warrant field trials against rice blast. While the initial
in planta results were promising, 24 could not match the almost
complete elimination of M. grisea infestation by the commercial
fungicide azoxystrobin (26) at low concentrations (12.5 ppm).26
Although the strategy to introduce vicinal diaxial oxygenation in
ring B has not, as yet, afforded the increase in some form of
bioactivity hoped for in 15 and 16 (we were unable to source this
compound from local specimens of E. rhinocerotis and 16 was
synthesized from commercially available sclareol),27 the seren-
dipitous discovery of the potentially useful fungicidal activity of
24 and 25 emphasizes the ongoing importance of attempting to
add value to natural products, whether they are of plant or
marine origin, through semisynthesis.
3.2. Sea Slugs, Malaria And Cancer
Sea slugs (also known as nudibranchs) are slow-moving,
soft-bodied, shell-less marine molluscs which prey on other
marine invertebrates, e.g. sponges and soft corals and do not
possess any visible means of physical protection against preda-
tion, e.g. a shell or spines. However, their striking colouration
warns potential predators that many of the sea slugs are chemi-
cally defended. While the majority of sea slug species sequester
their chemical defence metabolites from the marine invertebrates
on which they feed, a small number of these molluscs possess
the ability to synthesize their defensive metabolites de novo, e.g.
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the Mediterranean sea slug, Pleurobranchea meckelii.28
Given our interest in both terrestrial and marine labdane
diterpenes our attention was drawn to the isolation of two
reportedly unstable isomeric labdane diterpene aldehyde meta-
bolites: labd-13E-ene-8β-ol-15-al (27) and labd-13Z-ene-
8β-ol-15-al (28) from P. meckelii by Cimino and co-workers.28
Bioactivity investigations of marine natural products, especially
those isolated from nudibranchs, are frequently hampered by
the paucities of these compounds that are often available for
these studies.29 Struggling with the facile isomerisation of 27 and
28 on exposure to standard chromatography media Cimino and
co-workers were unable to isolate sufficient quantities of 27 and
28 for chemical ecology and bioactivity studies.28 We therefore
anticipated that the semisynthesis of these two compounds from
a commercially available terrestrial plant diterpene, e.g. manool
(29) could provide a possible solution to this particular marine
diterpene supply problem.30
A key intermediate in our synthesis was the diketone (30),
readily accessible from 29 via PCC oxidation followed by
reductive ozonolysis. A Wittig-type reaction regiospecifically
extended the side chain to give the esters (31 and 32) while a
Grignard addition efficiently introduced the methyl group at
C-8 with Re-facial selectivity. LAH reduction of the resultant
hydroxy-esters (33 and 34) yielded the diols (35 and 36) which
could be quantitatively converted into 27 and 28 by stirring with
manganese dioxide. This final synthetic step provided a facile
method to generate the natural products, 27 and 28, from a stable
precursor when required for chemical ecology or other bio-
activity studies and thus avoided the isomerization issues associ-
ated with the chromatography of these compounds.30
Again, the serendipitous discovery of a useful product from a
side reaction during the synthesis of 31 and 32, provided an
unexpected opportunity to synthesize a new series of bioactive
compounds.31 We found that the addition of excess NaH during
the Wittig step resulted in a quantitative conversion of 30 to the
crystalline 8-hydroxy-13-podocarpanone (37) via an intra-
molecular aldol condensation reaction. 8-Hydroxy-13-podo-
carpanone provided us with a suitable precursor for the further
Grignard and Wittig syntheses of a wide range of compounds
(e.g. 38, 39 and 40) analogous to the anti-plasmodial isopimarane
diterpene (41) isolated from the bark of a Turkish tree.32 Ongoing
structure activity relationship studies have revealed that 8β,
13β-dihydroxy-13α-phenylpodocarpane (39) yielded the most
significant anti-plasmodial activity of the cohort of compounds
prepared from 37 and was comparable with the activity reported
for the naturally occurring substances. Interestingly, 39 also
appeared to exhibit significant inhibition of in vitro β-hematin
formation which may provide an initial clue as to a possible
mechanism of action for these compounds against Plasmodium
falciparum.
Hypselodoris capensis is a colourful sea slug inhabiting the
sub-tidal reefs situated along the southern coast of South Africa.
Our initial investigations of the sequestered chemistry of
H. capensis revealed that this species obtained its major defensive
chemicals (β-substituted furanosesterterpenes, e.g. variabillin,
42) from a Fasciospongia sponge on which it was frequently
observed feeding in the Tsitsikamma National Park.33 Other
metabolites isolated from this species of sea slug, e.g. the
sesquiterpene nakafuran-8 (43), were not present in the
Fasciospongia sponge and a return to our underwater study site in
the Tsitsikamma National Park revealed that H. capensis
occasionally also feeds on a Dysidea sponge which we were
able to show was the source of 43 and another compound
tsitsikammafuran (44).34 Interestingly, 44 was not present in
extracts of H. capensis suggesting a possibly selective uptake of
sequestered metabolites by the sea slug. We were able to confirm
the structure of 44 through the synthesis of both 44 and its
regioisomer (45) through BuLi mediated halogen metal exchange
(HME) reactions of the brominated precursors 3-bromo-p-
cymene and 4-bromo-m-cymene with 3-furaldehyde.34 The low
yields (27–32 %) of the HME coupling reaction that afforded 44
and 45 are typical of HME reactions involving activated aromatic
rings and we initially encountered similar low yields in our
synthesis of analogues of the cytotoxic prenylated aromatic
compounds isolated from the endemic South African sea slug
Leminda millecra.
Leminda millecra is a common sea slug in Algoa Bay and seques-
ters a plethora of diverse bioactive metabolites from its diet of
soft corals and sea fans.35 Of interest to us was the cytotoxicity (8 –
60 µM) of several prenylated toluhydroquinones and toluqui-
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nones (e.g. 46 and 47) to oesophageal cancer cells. Oesophageal
cancer is particularly prevalent in the rural areas of the Eastern
Cape and over the last six years we have routinely screened
marine natural products against this form of cancer.36 Using a
cancer cell line (WHCO1), derived from a South African oesoph-
ageal cancer patient, we were able to establish the mechanism of
action of 43 which induces caspase 3 mediated apoptosis of
oesophageal cancer cells via the initial production of reactive
oxygen species and subsequent activation of the cJun/Erk signal-
ing pathway.37 The cytotoxicity observed for the prenylated
quinones isolated from L. millecra prompted an SAR study of
prenylated toluhydoquinones related to 46 and 47. Synthesis of
the simplified analogue (48), which proved to be similarly
cytotoxic (6 µM) to 43 (8 µM), was achieved via an HME reaction
between the aromatic bromide (49) and geranyl bromide fol-
lowed by cerium ammonium nitrate mediated oxidative
demethylation of the coupled product (50).38 The capriciously
variable and low yields of 50 (0–40 %) obtained from the HME
reaction prompted us to investigate the mechanism of this reac-
tion with a view to limiting the variability and improving the
yield. A detailed 7Li and 13C NMR study of lithium aggregation
occurring during this reaction enabled us to rationally change
the reaction conditions to reproducibly afford 50 in 60–65 %
yield.39 This reasonably successful resolution of the challenges
associated with the HME step provided an opportunity to
synthesize the hydroxylated and brominated prenylated
quinone precursors (e.g. 51–53) which will be oxidatively
methylated and screened against oesophageal cancer cells in
due course.38
3.3. Squeezing New Opportunities Out of Marine Sponges
The secondary metabolites produced by marine sponges
(Phylum Porifera) have provided the mainstay of global marine
natural product chemistry for nearly half a century. South Afri-
can sponges are no exception and they are an almost endless
source of new bioactive compounds, e.g. the topoisomerase
inhibitor, tsitsikammanine A (54)40 and the autophagy modulat-
ing amino sterol (55).41
Sponges are filter feeders that feed on microbes and small
particulate matter suspended in the water column. A sponge
weighing only a kilogram is able to filter thousands of litres of sea
water, rich in microbes, per day and it is therefore not surprising
that large and diverse microbial communities are retained inside
sponges which can, as reported for the giant barrel sponge
Xestospongia muta, make up as much as 40 % of the internal
volume of a sponge.42 Over the last 15 years it has become
increasingly apparent that many of the metabolites originally
attributed to sponge biosynthesis are in fact the secondary
metabolic products of the microbes that live in a symbiotic
relationship with the sponge. In this relationship the sponge
provides a living space and a source of nutrients for the microbes
while the microbes supply the sponge with toxic secondary
metabolites which are subsequently used as part of a chemical
defence strategy against predation of joint benefit to both
sponge and microbes. The factors that determine which
microbes the sponge consumes and which are retained as
symbionts are not clear.42 From a natural product perspective a
key indicator of a microbial, as opposed to a sponge, source for a
marine natural product are the occurrence of either the same
metabolite, e.g. manzamine A (56) in several unrelated species of
sponge43 or even in a different phylum, e.g. makaluvamine A
(57) which was originally isolated from a latrunculid sponge
(Zyzzia cf. marsailis)44 and has subsequently also been reported
from the fruiting bodies of a myxomycete (slime mould).45
Secondary metabolites containing a central pyrroloimino-
quinone structural scaffold, e.g. 54 and 57 have dominated our
studies of South African sponges from the Family Latrunculidae.
South Africa and New Zealand are global centres of latrunculid
sponge biodiversity and these green and brown pigmented
sponges are common along the many reefs that line the South
African coast. Pyrroloiminoquinone containing compounds are
generally highly cytotoxic and discorhabdin A (58), isolated from
a South African Latrunculia species, was found to be toxic to
human colon tumour cells at very low concentrations (7 nM).40
Regrettably, the apparent non-specific cytotoxicity of these
compounds has hampered their development as anti-cancer
drugs and we are unable to isolate sufficient quantities of these
compounds to embark on semi-synthetic programmes in an
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attempt to improve their selectivity and therapeutic index.
Given the well documented difficulties associated with
extracting sufficient amounts of bioactive metabolites from
marine organisms for clinical development, secondary metabo-
lite producing marine microbes may hold the key to the long
term development of bioactive marine natural products as
new pharmaceuticals.46 The isolation and culturing of marine
microbes is not trivial and has its own associated difficulties.42
However, our rapidly expanding knowledge of the gene clusters
responsible for bioactive natural product biosynthesis provides
an opportunity, once they have been identified, to transpose
these clusters into a heterologous host more amenable to large
scale propagation.2 If this process is successful further opportu-
nities arise to manipulate the relevant gene clusters in order
to generate an additional library of ‘unnatural’ secondary
metabolite analogues. As the unit cost of total genome sequenc-
ing continues to fall a significant shift in emphasis in global
natural product research is predicted and the future rational
targeting of those organisms with the genetic capacity to pro-
duce natural products of pharmaceutical interest may not be just
a pipe-dream.2
Therefore, of current interest to us are the microbial communi-
ties which inhabit latrunculid sponges belonging to the endemic
sponge genus Tsitsikamma. This endemic South African sponge
genus, originally discovered in the Tsitsikamma National Park,
has produced a number of bioactive pyrroloiminoquinone
natural products including the topoisomerase inhibitor, 54.40 The
close structural similarities between 54 and wakayin (59) a
secondary metabolite found in a completely unrelated marine
ascidian invertebrate (Clavelina sp.)47 would possibly suggest a
common microbial origin for these particular pyrroloimino-
quinone metabolites. The first step in our quest to investigate a
possible microbial source for 54 and related compounds has
involved an investigation of the microbial community structure
in different specimens of T. favus through analysis of microbial
16S RNA gene sequences isolated from the sponge tissue and
water squeezed out of freshly collected sponges.42 The second
step will be to compare the microbial community structure of the
two closely related Tsitsikamma species T. pedunculata and
T. scurra looking for any overlap in resident microbial species
which will hopefully provide insights into a possible common
microbial source for the tsitsikammamines and other
pyrroloiminoquinone metabolites.
4. Conclusion
Over the last decade the high-throughput screening of libraries
of synthetic compounds in international pharma’s drug discov-
ery programmes has increasingly diverted attention away from
natural products as a source of new drugs. Natural products are
biosynthesized by proteins and are often required to bind to
proteins to execute the bioactivities for which they are produced
by a living organism. As proteins only have a limited number of
fold types it should be explicit that many natural products have
privileged structures to bind to protein receptors and therefore
RESEARCH ARTICLE M.T. Davies-Coleman, 111
S. Afr. J. Chem., 2010, 63, 105–113,
<http://journals.sabinet.co.za/sajchem/>.
cannot be largely ignored as a source of new drugs for much
longer.2 Advances in separation and structure elucidation tech-
nologies coupled with a proliferation of new directed screening
methods, rapid genetic sequencing and a growing realization of
the potential of biosynthetic pathway exploitation to generate
an almost limitless library of natural product analogues, is
heralding a renaissance in international natural product based
drug discovery.2,12
South Africa has a rich history of natural products chemistry
research and is well placed to benefit from any renewed interna-
tional interest in natural products as a source of new pharma-
ceuticals. However, a perception from the current allocation of
research funding in South Africa would suggest that the future
of natural products research will increasingly become the
responsibility of botanists and ethnobotanists and this new
development must be challenged by South Africa’s organic
chemists who have been the custodians of natural products
chemistry in this country for over a century. Rigorous total
structure elucidation of bioactive organic natural products is the
basic prerequisite of internationally recognized natural product
chemistry and is of crucial importance to both the pharmaceutical
industry and synthetic chemists involved in natural product
total synthesis. It is also the legacy we inherited from Warren,
Rivett and others of their generations. Present and future South
African organic chemists should neither ignore the endless
opportunities associated with the unique biomolecular diversity
inherent in southern Africa’s enviable biological resources nor
voluntarily abdicate their responsibility to lead natural products
research in this country.
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